Report
Nyxoah - 7 months for the American DREAM to come true
Despite significant cut in TP, BUY reiteratedWe reviewed our estimates following the H1 23 results: 1/ we revised EU revenue estimates and delayed ramp-up based on performance so far, 2/ we raised our probability of success for the DREAM trial, 3/ we reviewed SG&A to better reflect US launch prep costs, 4/ we included the full dilution from the EUR 40.2m ATM offering.As a result, we cut our TP by 54%. However, based on our conviction about the competitive edge of the Genio system, our confidence in the DREAM trial outcome, the compelling US market demand, the access to the
Underlying
Nyxoah
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Laura Roba
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.